UNGA 2026 Political Accord Session: Precision Oncology Readiness
A high-level political session during UNGA 2026 focused on launching the New York Precision Oncology Readiness Accord. The session will frame precision oncology readiness as an access and implementation priority, bring together political, diplomatic, clinical, patient and stakeholder voices, and launch a 90-day validation process toward a 12-month implementation roadmap.
Event details
Event type
High-Level Political Lab
Format
Afternoon high-level political accord session during UNGA week, focused on precision oncology readiness, political endorsement, stakeholder alignment and launch of a 90-day validation process.
Audience
Political and diplomatic representatives, public authorities, clinical and scientific leaders, patient advocates, oncology and diagnostics experts, regional health-system leaders, global health institutions, industry partners, funders and implementation stakeholders.
Why this event matters
Precision oncology is no longer only a scientific challenge. It is an access and readiness challenge.
Patients may become eligible for biomarker testing, clinical trial enrolment, targeted treatment or specialist care, but still face avoidable delay because systems are not ready to act. The gap is not only about innovation. It is about whether diagnostics, referral, evidence generation, reimbursement, regional capacity and patient pathways can respond when science identifies that a patient may benefit.
This UNGA-week session creates a political and public moment for a practical readiness agenda. It will present the New York Precision Oncology Readiness Accord as a shared framework for improving access, strengthening implementation and launching a 90-day validation process.
Strategic frame
The New York Precision Oncology Readiness Accord is designed as a political and operational cooperation framework. It is not a treaty and does not create legal, regulatory, reimbursement, procurement or governmental obligations unless separately agreed in writing.
The Accord is built around a simple proposition: when science identifies that a patient is eligible for better care, the system must be ready to test, refer, enrol, treat or follow that patient without avoidable delay.
The afternoon session will provide the high-level political Accord moment. A possible linked morning technical readiness lab may provide additional input on trial readiness, biomarker and diagnostic readiness, disease demonstrator pathways and regional equity. If convened, its conclusions will inform the afternoon discussion and feed into the 90-day validation process.
Core question
How can political, clinical and stakeholder cooperation make precision oncology systems ready to act when a patient becomes eligible for better care?
Agenda snapshot
13:00-13:08 | Arrival, Protocol and Opening Welcome
Opening the high-level political Accord session
IPM Alliance and host representatives will frame the afternoon as the high-level political Accord session during UNGA week, focused on turning precision oncology readiness into a shared cooperation framework for validation and follow-up.
13:08-13:18 | Readiness Framing: From Eligibility to Action
Why precision oncology readiness is now an access priority
A short strategic framing of the precision oncology readiness challenge across clinical trials, biomarkers, diagnostics, disease pathways, evidence generation and regional equity.
13:18-13:30 | Patient and Doctor Access Moment
Eligible, but not reached
A patient and clinical access moment will frame the central problem: patients may become eligible for better care, but still fail to receive timely testing, referral, trial access, treatment or follow-up.
13:30-13:42 | Opening Political Address
Precision oncology readiness as a political and access priority
Political and institutional opening remarks will position the Accord within the wider UNGA-week agenda on health systems, innovation, equity and patient access.
13:42-13:57 | Scientific and Strategic Keynote
From precision oncology innovation to readiness
Scientific and strategic keynote interventions will connect the pace of precision oncology innovation with the system conditions required for diagnostics, trial access, targeted treatment and regional implementation.
13:57-14:17 | Global Readiness and Cooperation Round
Where international cooperation can improve precision oncology access
Global institutional and public-sector voices will discuss how international cooperation can strengthen diagnostics, evidence generation, clinical trial access, regional capacity and implementation support.
14:17-14:45 | Clinical and Regional Readiness Anchors
From system barriers to practical readiness priorities
Clinical, regional and stakeholder anchors will discuss where precision oncology readiness needs to improve, including diagnostics, disease pathways, evidence generation, industry contribution, clinical adoption and regional equity.
14:45-14:55 | Presentation of the New York Precision Oncology Readiness Accord
Readiness commitments and validation process
IPM Alliance will present the Accord and its readiness commitments, setting out the shared framework for validation and follow-up after the session.
14:55-15:15 | Endorsement Statements
Political and institutional support for the Accord
Pre-cleared diplomatic and institutional signatories will endorse the New York Precision Oncology Readiness Accord and confirm support for the 90-day validation process.
15:15-15:25 | Closing: From Accord to Validation
Next steps toward the 12-month roadmap
IPM Alliance will confirm next steps, including the 90-day validation process and the basis for a 12-month implementation roadmap.
15:25-15:30 | Protocol Photo
Signature moment and reception transition
Group photo and signature moment before transition to the reception and bilateral exchange.
15:30 onward | Reception and Bilateral Exchange
Informal follow-up and stakeholder discussion
Reception and bilateral exchange to support follow-up conversations, partner engagement and validation planning.
Tracks, labs or working groups
Precision Oncology Readiness
This track frames precision oncology as an access and readiness challenge. It focuses on whether health systems can act when a patient becomes eligible for biomarker testing, clinical trial enrolment, targeted treatment, specialist referral or follow-up.
Expected output:
Shared readiness framing for the New York Precision Oncology Readiness Accord and validation process.
Diagnostics, Trials and Evidence-to-Access
This track focuses on the system conditions required to connect biomarker testing, diagnostics, clinical trial evidence, regulatory confidence, reimbursement, real-world evidence and clinical adoption.
Expected output:
Readiness priorities across diagnostics, evidence generation, reimbursement and patient pathways.
Regional Equity and Implementation Cooperation
This track examines how precision oncology access can be strengthened across countries, regions and care settings, so that access does not depend only on geography, centre capacity or local expertise.
Expected output:
Cooperation priorities for regional readiness, equity and follow-up validation.
Accord Validation and Roadmap
This track focuses on the post-session pathway: endorsement of the Accord, launch of the 90-day validation process and development of the basis for a 12-month implementation roadmap.
Expected output:
90-day validation route and foundation for a 12-month implementation roadmap.
People and contributors
Denis Horgan
Expected outputs
This activity is designed to produce practical outputs that can support follow-up after the meeting. Depending on the format, outputs may include a public statement, implementation brief, consensus note, pathway prototype, readiness map, roadmap or stakeholder summary.
New York Precision Oncology Readiness Accord
90-Day Validation Process
12-Month Precision Oncology Readiness Roadmap
Readiness Commitments Summary
Related content
Biomarker Testing Is Rising, But Eligibility Still Gets Lost
Cancer Drugs Put Europe’s New HTA System to Its First Real Test
Cancer Sequencing Becomes the Operating System of Precision Oncology
ASCO 2026: Why oncology is also paying attention to GLP-1 medicines
AI Multiomics Moves Into the Trial Stratification Layer
FDA Puts AI Inside the Evidence Machine
IPM Brief – Issue 8 | The Trial Is Now a Border
Join us at New York Precision Oncology Readiness Accord
24 September 2026 | 20:00 - 21:00
Italian Cultural Institute, 686 Park Avenue, New York, NY 10065, United States, New York, United States • Global / North America
Interested in this event?
IPM Alliance welcomes engagement from policymakers, scientific experts, patient organisations, health-system leaders, industry partners and implementation actors.